Novo Nordisk's liraglutide beats standard therapy in study

06/8/2009 | Reuters

Novo Nordisk's diabetes drug liraglutide beat a commonly used rival, Sanofi-Aventis' glimepiride, in controlling blood sugar and caused some patients to lose weight, according to a two-year trial. The study showed a 1.1% decline in A1C blood-sugar levels in patients taking liraglutide compared with a 0.6% reduction in those taking glimepiride.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC